Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.58 Analyst target: $10.00 Upside: 1619.10%
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.